Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Emerg Infect Dis ; 29(2): 448-450, 2023 02.
Artículo en Inglés | MEDLINE | ID: mdl-36648111

RESUMEN

Monkeypox virus (MPXV) has gained interest because of a multicountry outbreak of mpox (formerly monkeypox) cases with no epidemiologic link to MPXV-endemic regions. We sequenced the complete genome of MPXV isolated from a patient in northern Mexico. Phylogenetic analysis grouped the virus with isolates from Germany.


Asunto(s)
Monkeypox virus , Mpox , Humanos , Monkeypox virus/genética , Filogenia , México/epidemiología , Mpox/diagnóstico , Mpox/epidemiología , Secuencia de Bases
3.
Med Clin (Barc) ; 162(10): 477-482, 2024 05 31.
Artículo en Inglés, Español | MEDLINE | ID: mdl-38342706

RESUMEN

BACKGROUND AND PURPOSE: Some studies have shown that influenza vaccination is associated with a lower risk of SARS-CoV-2 infection; in patients with COVID-19 infection, admission to intensive care is reduced, with less need for mechanical ventilation, shorter hospital stays, and reduced mortality. This study aimed to determine if a history of annual influenza vaccination impacts the clinical course of SARS-CoV-2 infection during hospitalization. METHODS: This was an observational, prospective, cohort study of patients older than 65 admitted to the COVID-19 unit from January to June 2021. The history of influenza vaccination over the last 5 years was assessed in each patient during hospitalization. We measured the length of hospital stay, the need for admission to the intensive care unit (ICU), the patient's oxygen requirements, complications during hospitalization, and outcome (medical discharge or death). Patients with a history of vaccination against SARS-CoV-2 were not included. RESULTS: We analyzed 125 patients, 50.4% (n=63) with history of influenza vaccination and 49.6% (n=62) without a history of influenza vaccination. In-hospital mortality was 44.8%, higher in the unvaccinated (54.8%) population (p=0.008). ICU admission was 27% higher in vaccinated (35%) patients (p=0.05). Patients without a history of influenza vaccination had a higher prevalence of cardiac (8% vs. 5%, p=0.04) and renal complications (29% vs. 13%, p=0.02). Patients with a history of vaccination had a greater need for invasive mechanical ventilation (25.4%, p=0.02). CONCLUSION: In this study, a history of influenza vaccination in older adults with SARS-CoV-2 infection was related to lower in-hospital mortality.


Asunto(s)
COVID-19 , Mortalidad Hospitalaria , Hospitalización , Vacunas contra la Influenza , Gripe Humana , Humanos , Anciano , COVID-19/prevención & control , COVID-19/complicaciones , COVID-19/mortalidad , COVID-19/epidemiología , Masculino , Femenino , Estudios Prospectivos , Hospitalización/estadística & datos numéricos , Anciano de 80 o más Años , Gripe Humana/prevención & control , Gripe Humana/mortalidad , Gripe Humana/epidemiología , Gripe Humana/complicaciones , Tiempo de Internación/estadística & datos numéricos , Vacunación , Respiración Artificial/estadística & datos numéricos , Unidades de Cuidados Intensivos
4.
Viral Immunol ; 36(4): 241-249, 2023 05.
Artículo en Inglés | MEDLINE | ID: mdl-36800236

RESUMEN

Individuals with no known comorbidities or risk factors may develop severe coronavirus disease 2019 (COVID-19). The present study assessed the effect of certain host polymorphisms and viral lineage on the severity of COVID-19 among hospitalized patients with no known comorbidities in Mexico. The analysis included 117 unrelated hospitalized patients with COVID-19. Patients were stratified by whether they required intensive care unit (ICU) admission: the ICU group (n = 40) and non-ICU group (n = 77). COVID-19 was diagnosed on the basis of a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reverse transcription-polymerase chain reaction (RT-PCR) assay and clinical and radiographic criteria. The presence of the IL1B-31 (T/C) polymorphism was determined for all patients using PCR and nucleotide sequencing. Genotyping of the IL-4 (-590, T/C) and IL-8 (-251, T/A) polymorphisms was performed by the amplification refractory mutation system-PCR method. Genotyping of IL1-RN was performed using PCR. Viral genome sequencing was performed using the ARTIC Network amplicon sequencing protocol using a MinION. Logistic regression analysis identified the carriage of IL-1 B*-31 *C as an independent potential risk factor (odds ratio [OR] = 3.1736, 95% confidence interval [CI] = 1.0748-9.3705, p = 0.0366) for ICU admission and the presence of IL-RN*2 as a protective factor (OR = 0.4371, 95% CI = 0.1935-0.9871, p = 0.0465) against ICU admission. Under the codominant model, the CC genotype of IL1B-31 significantly increased the risk of ICU admission (OR: 6.38, 95% CI: 11.57-25.86, p < 0.024). The IL1B-31 *C-IL-4-590 *T haplotype increased the risk of ICU admission (OR = 2.53, 95% CI = 1.02-6.25, p = 0.047). The 42 SARS-CoV-2 genomes sequenced belonged to four clades, 20A-20D. No association was detected between SARS-CoV-2 clades and ICU admission or death. Thus, in patients with no known comorbidities or risk factors, the IL1B-31*C proinflammatory allele was observed to be associated with the risk of ICU admission owing to COVID-19.


Asunto(s)
COVID-19 , Humanos , COVID-19/genética , SARS-CoV-2/genética , Alelos , Interleucina-4 , Hospitalización
5.
Hum Vaccin Immunother ; 18(7): 2150474, 2022 12 30.
Artículo en Inglés | MEDLINE | ID: mdl-36457300

RESUMEN

In Mexico, seasonal influenza epidemics results in substantial mortality and burden to healthcare resources. The country`s health authority provides vaccination to children <5 years old; adults >60 years of age; those aged 5-60 years with risk factors. Inclusion of school-aged children and adults until 59 years of old with no risk factors in the vaccination program would be highly beneficial. A prospective cohort surveillance study was conducted between the influenza seasons of 2014-2015 and 2018-2019 at the Dr. José Eleuterio González University Hospital. The primary outcome was need for hospitalization in vaccinated and unvaccinated patients with ILI or seasonal influenza. Secondary outcomes included outpatient management, admission to the ICU, and mortality during hospitalization among vaccinated and unvaccinated participants. 361patients (37.44%) had a confirmed influenza diagnosis. Being vaccinated made it more probable to be treated as an outpatient (p = .0001). For unvaccinated patients, the risk for hospitalization (OR = 1.70), ICU admission (OR = 8.46) and in-hospital death (OR = 27.17) was higher. Fifty-two patients died due to complications related to seasonal influenza or ILI, and none of them were vaccinated. Most subjects were between 18 and 49 years old. Influenza vaccination significantly reduced hospitalization, need for ICU admission, and in-hospital mortality in a 5-year study from Monterrey, Mexico.


Asunto(s)
Vacunas contra la Influenza , Gripe Humana , Niño , Adulto , Humanos , Persona de Mediana Edad , Preescolar , Adolescente , Adulto Joven , Gripe Humana/epidemiología , Gripe Humana/prevención & control , Estudios Prospectivos , Mortalidad Hospitalaria , México/epidemiología , Hospitalización , Vacunación
6.
Vaccines (Basel) ; 10(5)2022 Apr 21.
Artículo en Inglés | MEDLINE | ID: mdl-35632412

RESUMEN

Information regarding the efficacy of the recombinant adenovirus type-5-vectored (CanSino Bio) vaccine against the COVID-19 disease in a real-life setting is limited. A retrospective cohort study was carried out in the teaching university community of the metropolitan area of Monterrey, Mexico, through a four-section survey, and during the COVID-19 delta wave. Determination of IgG antibodies against SARS-CoV-2 spike (S) protein was performed in a subset of participants vaccinated with CanSino Bio. A total of 7468 teachers responded to the survey, and 6695 of them were fully vaccinated. Of those, 72.7% had CanSino Bio, 10.3% Pfizer, 8.4% AstraZeneca, 1.2% Moderna, and 2.7% others. Symptomatic breakthrough infections were recorded in those vaccinated with CanSino Bio (4.1%), AstraZeneca (2.1%), and Pfizer (2.2%). No difference was found between CanSino Bio and other vaccines regarding hospitalization, the need for mechanical ventilation, and death. For CanSino Bio recipients, anti-S antibodies were >50 AU/mL in 73.2%. In conclusion, primary breakthrough symptomatic infections were higher in the CanSino vaccinated group compared to other brands. Individuals with a previous infection had higher antibody levels than those who were reinfected and without infection. A boosted dose of CanSino is recommended for those individuals without a previous infection.

7.
J Microbiol Immunol Infect ; 54(5): 787-793, 2021 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-34294593

RESUMEN

OBJECTIVE: We aimed to analyze clinical outcomes from patients with severe COVID-19 pneumonia that received either baricitinib plus dexamethasone or dexamethasone monotherapy. METHODOLOGY: We performed a retrospective comparative study. Data from hospitalized patients with severe COVID-19 pneumonia (saturation <93%, bilateral pulmonary infiltrates) that were treated with baricitinib plus dexamethasone or dexamethasone were collected. Our primary objective was to compare overall mortality and secondly to compare progression to mechanical ventilation and over infection rates. RESULTS: A total of 793 patients were assessed for inclusion criteria, 596 were excluded and 197 were analyzed for primary outcome: 123 in the baricitinib plus dexamethasone group and 74 in the dexamethasone monotherapy group. The mean age was 59.9 years (SD ± 14.5) and 62.1% (123/197) were male. 42.9% (85/197) of the cases required ICU admission and 25.8% (51/197) underwent invasive mechanical ventilation (IMV). Overall thirty-day mortality was 27.9% (55/197); Mortality was significantly lower in the baricitinib plus dexamethasone group compared to the dexamethasone monotherapy group (20.3% vs 40.5%, P = <.05). There was no difference in hospital acquired infections between both groups. CONCLUSION: Thirty-day mortality was significantly lower in patients with COVID-19 pneumonia treated with baricitinib plus dexamethasone versus dexamethasone monotherapy. No difference was observed in progression to invasive mechanical ventilation and hospital acquired infections.


Asunto(s)
Azetidinas/uso terapéutico , Tratamiento Farmacológico de COVID-19 , Dexametasona/uso terapéutico , Purinas/uso terapéutico , Pirazoles/uso terapéutico , Sulfonamidas/uso terapéutico , Anciano , Quimioterapia Combinada , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , SARS-CoV-2/efectos de los fármacos
8.
Cardiol Res ; 11(4): 260-265, 2020 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-32595812

RESUMEN

Although coronavirus disease 2019 (COVID-19) manifests in most cases with respiratory symptoms, other presentations can occur. Direct damage to the cardiovascular system has been reported and recently, acute myocardial injury has been identified as a risk factor for mortality. Transthoracic echocardiography is a non-invasive tool that allows the detection of myocardial damage with validated markers (left ventricular ejection fraction and global longitudinal strain). Herein, we present the echocardiographic findings in four patients with COVID-19. All cases had acute respiratory distress syndrome (100%). Three out of four had elevated levels of creatine kinase and creatine kinase myocardial band. One case had ventricular concentric remodeling (25%). All cases (100%) had altered ventricular function: two had a reduced ejection fraction (50%) and, of those available for global longitudinal strain analysis, all had abnormal global longitudinal strain (100%). One case was found to have a tricuspid vegetation of 12 × 10 mm with no other manifestation of endocarditis. All of our cases had left ventricular dysfunction as assessed by echocardiography. One of our patients had a vegetation in the tricuspid valve. Two of our cases had a reduced ejection fraction. The importance of acute cardiac injury in COVID-19 has recently been established. A recent study found it to be an independent risk factor for mortality in patients with this disease. Information regarding echocardiographic characteristics of this population is scarce. Further research to elucidate the impact of these characteristics on morbidity and mortality is urgently needed.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA